Skinsee Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 9 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 24.03%
(FY 2023)
- Profit 21.13%
(FY 2023)
- Ebitda 20.92%
(FY 2023)
- Net Worth -12.28%
(FY 2023)
- Total Assets -21.42%
(FY 2023)
About Skinsee Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jagdishkumar Sakhiya, Damjibhai Naranbhai, Rupalben Sakhiya, and One other member serve as directors at the Company.
- CIN/LLPIN
U51900GJ2015PTC084485
- Company No.
084485
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Sep 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Skinsee Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jagdishkumar Sakhiya  | Director | 14-Sep-2015 | Current |
| Damjibhai Naranbhai | Director | 14-Sep-2015 | Current |
| Rupalben Sakhiya | Director | 14-Sep-2015 | Current |
| Bhartiben Roy | Director | 14-Sep-2015 | Current |
Financial Performance and Corporate Structure Insights of Skinsee Pharma.
Skinsee Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 24.03% increase. The company also saw a substantial improvement in profitability, with a 21.13% increase in profit. The company's net worth observed a substantial decline by a decrease of 12.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skinsee Pharma?
In 2023, Skinsee Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sakhiya Skin Clinic LimitedActive 13 years 9 monthsJagdishkumar Sakhiya, Damjibhai Naranbhai and 1 more are mutual person
Dr. Sakhiya's Advanced Skin Science LlpActive 1 year 2 monthsJagdishkumar Sakhiya and Rupalben Sakhiya are mutual person
- Reflect Healthcare Science Private LimitedActive 4 years 2 months
Jagdishkumar Sakhiya, Damjibhai Naranbhai and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Skinsee Pharma?
Unlock and access historical data on people associated with Skinsee Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skinsee Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skinsee Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
